| 商品名称 | Lamivudine Teva |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Hepatitis B, Chronic |
| 通用名/非专利名称 | lamivudine |
| 活性成分 | lamivudine |
| 产品号 | EMEA/H/C/001113 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | J05AF05 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | Yes |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2009/10/23 |
| 上市许可开发者/申请人/持有人 | Teva B.V. |
| 人用药物治疗学分组 | Antivirals for systemic use |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2024/06/06 |
| 修订号 | 14 |
| 治疗适应症 | Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with: compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1). |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2018/05/18 |
| 最后更新日期 | 2024/06/07 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/lamivudine-teva-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva |